These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 22306123)

  • 1. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oximinoarylsulfonamides as potent HIV protease inhibitors.
    Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.
    Weber IT; Waltman MJ; Mustyakimov M; Blakeley MP; Keen DA; Ghosh AK; Langan P; Kovalevsky AY
    J Med Chem; 2013 Jul; 56(13):5631-5. PubMed ID: 23772563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
    Ghosh AK; Chapsal BD; Baldridge A; Steffey MP; Walters DE; Koh Y; Amano M; Mitsuya H
    J Med Chem; 2011 Jan; 54(2):622-34. PubMed ID: 21194227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
    Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
    J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
    Wu X; Ohrngren P; Ekegren JK; Unge J; Unge T; Wallberg H; Samuelsson B; Hallberg A; Larhed M
    J Med Chem; 2008 Feb; 51(4):1053-7. PubMed ID: 18215014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
    Ghosh AK; Xu CX; Rao KV; Baldridge A; Agniswamy J; Wang YF; Weber IT; Aoki M; Miguel SG; Amano M; Mitsuya H
    ChemMedChem; 2010 Nov; 5(11):1850-4. PubMed ID: 20827746
    [No Abstract]   [Full Text] [Related]  

  • 13. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors.
    He M; Zhang H; Yao X; Eckart M; Zuo E; Yang M
    Chem Biol Drug Des; 2010 Aug; 76(2):174-80. PubMed ID: 20572811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
    Windsor IW; Raines RT
    Sci Rep; 2015 Aug; 5():11286. PubMed ID: 26261098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
    Kovalevsky AY; Ghosh AK; Weber IT
    J Med Chem; 2008 Oct; 51(20):6599-603. PubMed ID: 18808097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
    Rocheblave L; Bihel F; De Michelis C; Priem G; Courcambeck J; Bonnet B; Chermann JC; Kraus JL
    J Med Chem; 2002 Jul; 45(15):3321-4. PubMed ID: 12109915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
    Dandache S; Sévigny G; Yelle J; Stranix BR; Parkin N; Schapiro JM; Wainberg MA; Wu JJ
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4036-43. PubMed ID: 17638694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
    Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
    J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.